Despite remarkable success in treating obesity, glucagon‐like peptide‐1 receptor agonists (GLP1‐RAs) face challenges including limited efficacy in some individuals, gastrointestinal side effects, potential muscle mass loss and rapid weight rebound after treatment. There is considerable interest in identifying complementary non-GLP-1RA-based approaches for modulating body weight. Writing in Cell Chem. Biol., Fu et al. now report that pharmacological inhibition of phosphotriesterase-related (PTER) reduces food intake and body weight in obese mice and achieves additive weight loss in combination with GLP1-R agonism.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
27,99 € / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
265,23 € per year
only 22,10 € per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
